PE20190327A1 - Complejos radio-farmaceuticos - Google Patents
Complejos radio-farmaceuticosInfo
- Publication number
- PE20190327A1 PE20190327A1 PE2018003200A PE2018003200A PE20190327A1 PE 20190327 A1 PE20190327 A1 PE 20190327A1 PE 2018003200 A PE2018003200 A PE 2018003200A PE 2018003200 A PE2018003200 A PE 2018003200A PE 20190327 A1 PE20190327 A1 PE 20190327A1
- Authority
- PE
- Peru
- Prior art keywords
- tissue
- targets
- similarity
- sequences
- sequence identity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a un metodo para la formacion de un complejo de torio que se dirige al tejido, comprendiendo dicho metodo: a) formar un quelante octadentado de formula (I) o (II), donde Rc es un resto ligante que termina en un resto acido carboxilico, tal como [-CH2-Ph-N(H)-C(=O)-CH2-CH2-C(C(=O)OH], entre otros, donde Ph es un grupo fenileno, preferentemente un grupo para-fenileno; b) acoplar dicho quelante octadentado a un resto que se dirige al tejido que comprende una cadena peptidica con identidad o similitud de secuencia con una de las secuencias 1, 11 o 21; y una cadena peptidica con identidad o similitud de secuencias con una de la secuencias 5,15 o 25; generando de ese modo un agente quelante que se dirige al tejido; y c) contactar dicho agente quelante que se dirige al tejido con una solucion acuosa que comprende 4+ iones del isotopo del torio emisor alfa227Th. Tambien se refiere al uso de este complejo de torio, para el tratamiento de una enfermedad neoplasica o hiperplasica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173874 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190327A1 true PE20190327A1 (es) | 2019-03-05 |
Family
ID=56132786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003200A PE20190327A1 (es) | 2016-06-10 | 2017-06-06 | Complejos radio-farmaceuticos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190298865A1 (es) |
| EP (1) | EP3468619A1 (es) |
| JP (1) | JP2019517547A (es) |
| KR (1) | KR20190016544A (es) |
| CN (1) | CN109689115A (es) |
| AR (1) | AR110466A1 (es) |
| AU (1) | AU2017277463A1 (es) |
| BR (1) | BR112018075554A2 (es) |
| CA (1) | CA3026900A1 (es) |
| CL (1) | CL2018003550A1 (es) |
| CO (1) | CO2018013359A2 (es) |
| CR (1) | CR20180581A (es) |
| CU (1) | CU20180149A7 (es) |
| DO (1) | DOP2018000277A (es) |
| EA (1) | EA201892814A1 (es) |
| EC (1) | ECSP18091468A (es) |
| IL (1) | IL263538A (es) |
| MA (1) | MA45225A (es) |
| MX (1) | MX2018015340A (es) |
| NI (1) | NI201800136A (es) |
| PE (1) | PE20190327A1 (es) |
| PH (1) | PH12018502605A1 (es) |
| SG (1) | SG11201810967VA (es) |
| TW (1) | TW201805025A (es) |
| UY (1) | UY37286A (es) |
| WO (1) | WO2017211809A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3426245B1 (en) | 2016-03-07 | 2022-12-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| UY37861A (es) | 2017-08-28 | 2019-03-29 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| CN112955142A (zh) | 2018-09-21 | 2021-06-11 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| BR112021009854A2 (pt) | 2018-11-21 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | heterociclos funcionalizados como agentes antivirais |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US20220273831A1 (en) | 2019-07-08 | 2022-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2021005131A1 (en) | 2019-07-08 | 2021-01-14 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US20230072421A1 (en) | 2019-07-25 | 2023-03-09 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4274835A1 (en) | 2021-01-07 | 2023-11-15 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US8173800B2 (en) | 2006-08-15 | 2012-05-08 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
| EP2483316A1 (en) | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| EP2516407A4 (en) * | 2009-12-24 | 2013-06-12 | Lumiphore Inc | RADIOPHARMACEUTICAL COMPLEXES |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| NL2009131C2 (en) * | 2012-07-05 | 2014-01-07 | Stichting Vu Vumc | Compound and use of compound to prepare a radiollabelled compound. |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
-
2017
- 2017-06-06 CA CA3026900A patent/CA3026900A1/en not_active Abandoned
- 2017-06-06 CR CR20180581A patent/CR20180581A/es unknown
- 2017-06-06 KR KR1020197000406A patent/KR20190016544A/ko unknown
- 2017-06-06 AU AU2017277463A patent/AU2017277463A1/en not_active Abandoned
- 2017-06-06 CU CU2018000149A patent/CU20180149A7/es unknown
- 2017-06-06 US US16/308,307 patent/US20190298865A1/en not_active Abandoned
- 2017-06-06 EP EP17729086.3A patent/EP3468619A1/en not_active Withdrawn
- 2017-06-06 SG SG11201810967VA patent/SG11201810967VA/en unknown
- 2017-06-06 JP JP2018564263A patent/JP2019517547A/ja active Pending
- 2017-06-06 BR BR112018075554A patent/BR112018075554A2/pt not_active Application Discontinuation
- 2017-06-06 MX MX2018015340A patent/MX2018015340A/es unknown
- 2017-06-06 MA MA045225A patent/MA45225A/fr unknown
- 2017-06-06 WO PCT/EP2017/063689 patent/WO2017211809A1/en unknown
- 2017-06-06 EA EA201892814A patent/EA201892814A1/ru unknown
- 2017-06-06 PE PE2018003200A patent/PE20190327A1/es unknown
- 2017-06-06 CN CN201780049257.8A patent/CN109689115A/zh active Pending
- 2017-06-09 TW TW106119188A patent/TW201805025A/zh unknown
- 2017-06-09 UY UY0001037286A patent/UY37286A/es not_active Application Discontinuation
- 2017-06-09 AR ARP170101585A patent/AR110466A1/es unknown
-
2018
- 2018-12-06 IL IL263538A patent/IL263538A/en unknown
- 2018-12-10 EC ECSENADI201891468A patent/ECSP18091468A/es unknown
- 2018-12-10 CO CONC2018/0013359A patent/CO2018013359A2/es unknown
- 2018-12-10 CL CL2018003550A patent/CL2018003550A1/es unknown
- 2018-12-10 DO DO2018000277A patent/DOP2018000277A/es unknown
- 2018-12-10 PH PH12018502605A patent/PH12018502605A1/en unknown
- 2018-12-10 NI NI201800136A patent/NI201800136A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2018013359A2 (es) | 2018-12-14 |
| CN109689115A (zh) | 2019-04-26 |
| UY37286A (es) | 2018-01-31 |
| US20190298865A1 (en) | 2019-10-03 |
| MX2018015340A (es) | 2019-03-28 |
| NI201800136A (es) | 2019-04-29 |
| IL263538A (en) | 2019-01-31 |
| MA45225A (fr) | 2019-04-17 |
| CR20180581A (es) | 2019-02-11 |
| AU2017277463A1 (en) | 2019-01-03 |
| WO2017211809A1 (en) | 2017-12-14 |
| JP2019517547A (ja) | 2019-06-24 |
| EA201892814A1 (ru) | 2019-06-28 |
| SG11201810967VA (en) | 2019-01-30 |
| EP3468619A1 (en) | 2019-04-17 |
| CA3026900A1 (en) | 2017-12-14 |
| CU20180149A7 (es) | 2019-07-04 |
| BR112018075554A2 (pt) | 2019-10-01 |
| CL2018003550A1 (es) | 2019-02-01 |
| PH12018502605A1 (en) | 2019-10-21 |
| KR20190016544A (ko) | 2019-02-18 |
| ECSP18091468A (es) | 2018-12-31 |
| AR110466A1 (es) | 2019-04-03 |
| TW201805025A (zh) | 2018-02-16 |
| DOP2018000277A (es) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190327A1 (es) | Complejos radio-farmaceuticos | |
| ECSP17038089A (es) | Complejos radiofarmacéuticos | |
| AR104350A1 (es) | Celulosa o derivado celulósico que incluye grupos de acrilamida o ácido acrílico injertados para tratar formaciones subterráneas | |
| UY35147A (es) | Anticuerpos anti-ceacam5 y usos de éstos. | |
| CO2018010024A2 (es) | Complejos radiofarmacéuticos | |
| UY37064A (es) | Método de purificación | |
| CL2021003525A1 (es) | Ligandos de antígeno de membrana específico de próstata (psma) y sus usos | |
| AR107298A1 (es) | Método de purificación | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| AR107300A1 (es) | Método para la preparación de isótopos | |
| BR112017023145A2 (pt) | Método para produzir um conjugado de proteína- peg | |
| AR102149A1 (es) | Anticuerpos dirigidos contra ticagrelor y métodos para su uso | |
| UA129038U (uk) | Комплекс сполук гумінових та вульвокислот з лужними металами | |
| CL2018001656A1 (es) | Procedimiento para la preparación de un agente quelante | |
| NZ723017A (en) | Method of cleansing the colon | |
| RU2015117313A (ru) | Способ лечения ран у животных | |
| AR095503A1 (es) | Inyección intratesticular de inmunógenos | |
| AR107436A1 (es) | Vacunas contra el cáncer | |
| MY194760A (en) | Methods and Systems Employing a Sulfonated Iminodiacetic Acid During Subterranean Treatment Operations | |
| AR090675A1 (es) | Compuesto limpiador y abrillantador y procedimiento para producir dicho compuesto |